Thermo Fisher ScientificvsExagen

TMO and XGN stock compared: price, dividend, valuation and results, from SEC filings.

TMO

Thermo Fisher Scientific Inc

$691.33

Value $257B

-1.27%
TMO's page

Thermo Fisher Scientific (TMO) has a market value of $257B and Exagen (XGN) $96M. Over the last year, with dividends, TMO moved +19.9% and XGN -58.2%. Dividend yield: TMO 0.27%, XGN none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    TMO$257B

    XGN$96M

    TMO is 2,670 times XGN

  • Revenue, 12 months

    TMO$47.4B

    XGN$72M

    TMO is 655 times XGN

  • Net income, 12 months

    TMO$7.1B

    XGN-$18M

  • Operating margin

    TMO17.9%

    XGN-20.1%

    38.0 points apart

  • ROIC

    TMO8.2%

    XGN-30.1%

    38.3 points apart

  • P/E

    TMO36.3

    XGN–

  • Dividend yield

    TMO0.3%

    XGN0.0%

    0.3 points apart

  • 5-year return

    TMO+10.9%

    XGN-70.3%

    81.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

TMO+10.9%

XGN-70.3%

5010020222023202420252026
Returns by period
PeriodTMOWith dividendsXGNWith dividends
1 year since November 14, 2025+19.9%Price +19.5%-58.2%Price -58.2%
3 years since November 16, 2023+47.7%+13.9% a yearPrice +46.3%+135.6%+33.1% a yearPrice +135.6%
5 years since November 15, 2021+10.9%+2.1% a yearPrice +9.3%-70.3%-21.5% a yearPrice -70.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

TMOThermo Fisher ScientificXGNExagen

Valuation

TMOXGN
Valuation
Price$691.33$3.77
Market value$257B$96M
Enterprise value (EV)$292B–
P/E36.3–
P/E, 5-year median32.7–
P/B4.77.0
EV/EBIT34.5–
Free cash flow yield3.0%–

Results and growth

TMOXGN
Results and growth
Revenue, 12 months$47.4B$72M
Net income, 12 months$7.1B-$18M
Free cash flow, 12 months$7.6B-$13M
Earnings per share, 12 months$18.96-$0.75
Revenue growth, year on year3.9%19.7%
Revenue growth a year, past+6.7%over 5 years+9.7%over 5 years
EPS growth a year, past+2.1%over 5 years–

Margins and returns on capital

TMOXGN
Margins and returns on capital
Gross margin–58.7%
Operating margin17.9%-20.1%
Net margin14.9%-25.1%
ROIC8.2%-30.1%
ROE13.4%-119.5%

Balance sheet

TMOXGN
Balance sheet
Cash$6.1B$28M
Total debt$41.4B–
Net debt / EBITDA3.7–
Interest cover5.5×-2.9×

Dividends and buybacks

TMOXGN
Dividends and buybacks
Dividend yield0.3%–
Dividend per share, 12 months$1.84–
Dividend growth a year, past+14.3%over 5 years–
Buyback yield1.2%–
Shareholder yield1.4%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: TMO or XGN

Didn't find what you were looking for?

Ask us
Which is bigger, Thermo Fisher Scientific or Exagen?

By market value, Thermo Fisher Scientific ($257B) is about 2,670.0 times Exagen ($96M), at today's prices.

How did TMO and XGN stock do over the last 5 years?

Since November 15, 2021, TMO's price moved +9.3% and XGN's -70.3%. With dividends: TMO +10.9% (+2.1% a year), XGN -70.3% (-21.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, TMO or XGN?

The dividend yield at today's price is 0.27% for Thermo Fisher Scientific and none for Exagen. Over the last twelve months they paid $1.84 and – per share.

Which has the higher profit margins, Thermo Fisher Scientific or Exagen?

Over the last twelve months, the net margin was 14.9% for Thermo Fisher Scientific and -25.1% for Exagen, and the operating margin 17.9% and -20.1%. Revenue was $47.4B and $72M.

Which is the better investment, Thermo Fisher Scientific or Exagen?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.